Effect of scheduled monitoring of liver function during anti-Tuberculosis treatment in a retrospective cohort in China

• Main Authors: Wu Shanshan, Xia Yinyin, Lv Xiaozhen, Zhang Yuan, Tang Shaowen, Yang Zhirong, Tu Dehua, Deng Peiyuan, Cheng Shiming, Wang Xiaomeng, Yuan Yanli, Liu Feiying, Hu Daiyu, Zhan Siyan
• Format: Article
• Language: English
• Published: BMC 2012-06-01
• Series: BMC Public Health
• Subjects: Tuberculosis; Hepatotoxicity; Monitoring
• Online Access: http://www.biomedcentral.com/1471-2458/12/454

<p>Abstract</p> <p>Background</p> <p>Data on effect of regular liver function monitoring during anti-TB treatment is limited in China. This study aimed to evaluate the effects of scheduled liver function monitoring on identification of asymptomatic liver damage and anti-TB treatment outcomes during anti-TB treatment.</p> <p>Methods</p> <p>A retrospective analysis was performed based on a national-level cohort study. A total of 273 patients developing liver dysfunction were divided into two groups, 111 patients who were diagnosed through scheduled liver function test within two months after initiation of anti-TB treatment formed scheduled monitoring group, others who were diagnosed due to developing symptoms formed passive detection group (n = 162). The two groups were compared through clinical features, prognosis of liver dysfunction and impact on anti-TB treatment using propensity score weighting analysis.</p> <p>Results</p> <p>33.3% of 273 patients did not have any clinical symptoms, including 8 with severe hepatotoxicity. 1.8% in scheduled monitoring group and 11.1% in passive detection group required hospitalization (P = 0.004). Regarding the prognosis of liver dysfunction, most patients recovered, no death happened in scheduled monitoring group while 3 died in passive detection group. In terms of impact on anti-TB treatment, 35.1% in scheduled monitoring group and 56.8% in passive detection group changed their anti-TB treatment (P = 0.001).</p> <p>Conclusions</p> <p>Scheduled monitoring is effective in identifying asymptomatic liver damage, reducing hospitalization rate and improving compliance of anti-TB treatment.</p>